{"nctId":"NCT00168298","briefTitle":"A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","startDateStruct":{"date":"2004-11-01","type":"ACTUAL"},"conditions":["Macular Edema","Retinal Vein Occlusion"],"count":668,"armGroups":[{"label":"700 µg Dexamethasone","type":"EXPERIMENTAL","interventionNames":["Drug: 700 µg Dexamethasone"]},{"label":"350 µg Dexamethasone followed by 700 µg Dexamethasone","type":"EXPERIMENTAL","interventionNames":["Drug: 700 µg Dexamethasone","Drug: 350 µg Dexamethasone"]},{"label":"Sham Injection followed by 700 µg Dexamethasone","type":"SHAM_COMPARATOR","interventionNames":["Drug: 700 µg Dexamethasone","Other: Sham Injection"]}],"interventions":[{"name":"700 µg Dexamethasone","otherNames":["Posurdex®"]},{"name":"350 µg Dexamethasone","otherNames":["Posurdex®"]},{"name":"Sham Injection","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* 18 years of age or older with macular edema resulting from retinal vein occlusion\n* Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse)\n* Visual acuity in other eye no worse than 20/200\n\nKey Exclusion Criteria:\n\n* Known anticipated need for ocular surgery within next 12 months\n* History of glaucoma or current high eye pressure requiring more than 1 medication\n* Diabetic retinopathy\n* Uncontrolled systemic disease\n* Known steroid-responder\n* Use of systemic steroids\n* Use of warfarin/heparin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The numbers of patients with at least a 15 or more letter improvement in BCVA in the study eye are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Retinal Thickness in the Study Eye","description":"Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"573.6","spread":"189.08"},{"groupId":"OG001","value":"566.6","spread":"219.63"},{"groupId":"OG002","value":"542.5","spread":"185.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-215.6","spread":"207.62"},{"groupId":"OG001","value":"-205.5","spread":"216.25"},{"groupId":"OG002","value":"-91.1","spread":"191.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-132.1","spread":"207.20"},{"groupId":"OG001","value":"-150.5","spread":"220.78"},{"groupId":"OG002","value":"-127.4","spread":"197.77"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With a Change From Baseline in BCVA by Category","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and \\<15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and \\<15 Letters Worsening, and ≥15 Letters Worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"25.7","spread":null},{"groupId":"OG002","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":null},{"groupId":"OG001","value":"39.0","spread":null},{"groupId":"OG002","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"26.6","spread":null},{"groupId":"OG002","value":"29.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"6.4","spread":null},{"groupId":"OG002","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"2.3","spread":null},{"groupId":"OG002","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With a Change From Baseline in BCVA by Category","description":"BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and \\<15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and \\<15 Letters Worsening, and ≥15 Letters Worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"21.6","spread":null},{"groupId":"OG002","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"33.9","spread":null},{"groupId":"OG002","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"28.9","spread":null},{"groupId":"OG002","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"10.6","spread":null},{"groupId":"OG002","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"5.0","spread":null},{"groupId":"OG002","value":"12.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":225},"commonTop":["Intraocular pressure increased","Conjunctival haemorrhage","Conjunctival hyperaemia","Eye pain","Hypertension"]}}}